U.S. Markets closed

Newron Pharmaceuticals S.p.A. (NWRN.SW)

Swiss - Swiss Delayed Price. Currency in CHF
Add to watchlist
15.50-0.10 (-0.64%)
At close: 5:31PM CEST
Full screen
Previous Close15.60
Bid15.40 x 0
Ask15.90 x 0
Day's Range14.90 - 15.80
52 Week Range14.85 - 28.70
Avg. Volume45,328
Market Cap245.12M
PE Ratio (TTM)-13.06
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters6 months ago

    FDA approves Newron's drug as add-on therapy for Parkinson's

    Newron Pharmaceuticals SpA said on Tuesday the U.S. Food and Drug Administration approved its Parkinson's disease treatment Xadago as an add-on therapy to levodopa, a drug widely used to treat the disease. Levodopa was developed in the late 1960s and is the first-line treatment for the management of Parkinson's, according to the National Parkinson Foundation. Xadago received European approval in 2015, and has been launched by Newron's parnter Zambon SpA in several countries including Germany, Italy Spaion and UK.

  • We're sorry this is all we were able to find about this topic.